Nanomedicine for Treating Diabetic Retinopathy Vascular Degeneration

Journal of International Translational Medicine Pub Date : 2021-11-24 DOI:10.3390/ijtm1030018

Tatiana Borodina, D. Kostyushev, A. Zamyatnin, A. Parodi

{"title":"Nanomedicine for Treating Diabetic Retinopathy Vascular Degeneration","authors":"Tatiana Borodina, D. Kostyushev, A. Zamyatnin, A. Parodi","doi":"10.3390/ijtm1030018","DOIUrl":null,"url":null,"abstract":"The incidence of diabetes and the pathological conditions associated with chronic hyperglycemia is increasing worldwide. Among them, diabetic retinopathy represents a leading cause of vision loss, causing a significant structural and functional impairment of the retinal and choroidal capillary network. Current therapies include anti-angiogenic and anti-inflammatory drugs administered through repetitive and invasive intraocular injections, and associated with significant adverse effects. The presence of ocular barriers affects the efficiency of topically administered therapeutics for treating the posterior segment of the eye. In this scenario, nanomedicine could improve current therapies for diabetic retinopathy by providing tools that can decrease the number of injections thanks to their controlled release properties, while some materials showed a natural ability to mitigate pathological neo-angiogenesis. Moreover, specific surface modifications could open new scenarios for the development of topical treatments. This review describes current advances in generating nanomedicine for diabetic retinopathy, focusing on the properties of the different materials tested explicitly for this purpose.","PeriodicalId":43005,"journal":{"name":"Journal of International Translational Medicine","volume":"3 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of International Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/ijtm1030018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 4

Abstract

The incidence of diabetes and the pathological conditions associated with chronic hyperglycemia is increasing worldwide. Among them, diabetic retinopathy represents a leading cause of vision loss, causing a significant structural and functional impairment of the retinal and choroidal capillary network. Current therapies include anti-angiogenic and anti-inflammatory drugs administered through repetitive and invasive intraocular injections, and associated with significant adverse effects. The presence of ocular barriers affects the efficiency of topically administered therapeutics for treating the posterior segment of the eye. In this scenario, nanomedicine could improve current therapies for diabetic retinopathy by providing tools that can decrease the number of injections thanks to their controlled release properties, while some materials showed a natural ability to mitigate pathological neo-angiogenesis. Moreover, specific surface modifications could open new scenarios for the development of topical treatments. This review describes current advances in generating nanomedicine for diabetic retinopathy, focusing on the properties of the different materials tested explicitly for this purpose.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

纳米药物治疗糖尿病视网膜病变血管变性

糖尿病的发病率和与慢性高血糖相关的病理状况在世界范围内正在增加。其中，糖尿病性视网膜病变是导致视力丧失的主要原因，引起视网膜和脉络膜毛细血管网络的严重结构和功能损害。目前的治疗方法包括通过反复和侵入性眼内注射抗血管生成和抗炎药物，并伴有明显的不良反应。眼屏障的存在影响了局部给药治疗眼后段的效率。在这种情况下，纳米医学可以通过提供减少注射次数的工具来改善糖尿病视网膜病变的现有治疗方法，这要多亏了它们的控释特性，而一些材料显示出减轻病理性新血管生成的天然能力。此外，特定的表面修饰可以为局部治疗的发展开辟新的前景。本文综述了目前用于糖尿病视网膜病变的纳米药物的进展，重点介绍了为此目的明确测试的不同材料的特性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of International Translational Medicine MEDICINE, RESEARCH & EXPERIMENTAL-

自引率

0.00%

发文量

317

审稿时长

8 weeks

期刊介绍： Journal of International Translational Medicine (JITM, ISSN 2227-6394), founded in 2012, is an English academic journal published by Journal of International Translational Medicine Co., Ltd and sponsored by International Fderation of Translational Medicine. JITM is an open access journal freely serving to submit, review, publish, read and download full text and quote. JITM is a quarterly publication with the first issue published in March, 2013, and all articles published in English are compiled and edited by professional graphic designers according to the international compiling and editing standard. All members of the JITM Editorial Board are the famous international specialists in the field of translational medicine who come from twenty different countries and areas such as USA, Britain, France, Germany and so on.